--- title: "Analyst Reiterates Buy on Dianthus as Claseprubart Data Momentum and New Pipeline Assets Strengthen Risk-Reward Profile" type: "News" locale: "en" url: "https://longbridge.com/en/news/299429976.md" description: "William Blair analyst Myles Minter reiterated a Buy rating on Dianthus (DNTH) on September 11, citing strong momentum in claseprubart’s pipeline and an improved risk-reward profile. Key drivers include the full enrollment of the Phase II MoMeNtum trial with data expected in December, robust interim efficacy in the CAPTIVATE study showing a 75% response rate, and attractive optionality from new assets DNTH-212 and DNTH-312. Additionally, J.P. Morgan initiated coverage with a Buy rating and a $135 price target." datetime: "2026-09-18T09:55:20.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/299429976.md) - [en](https://longbridge.com/en/news/299429976.md) - [zh-HK](https://longbridge.com/zh-HK/news/299429976.md) generator: "portal-rs" --- # Analyst Reiterates Buy on Dianthus as Claseprubart Data Momentum and New Pipeline Assets Strengthen Risk-Reward Profile William Blair analyst Myles Minter has reiterated their bullish stance on DNTH stock, giving a Buy rating on September 11. Myles Minter has given his Buy rating due to a combination of factors pointing to growing momentum in Dianthus’s pipeline and a favorable risk-reward profile. He highlights that claseprubart’s Phase II MoMeNtum trial in multifocal motor neuropathy is fully enrolled, with data expected in December, positioning the company to broaden proof-of-concept across several high-value autoimmune neuromuscular diseases. Minter also underscores the robust interim efficacy seen in the CAPTIVATE study in chronic inflammatory demyelinating polyradiculoneuropathy, where a 75% response rate has been maintained as more patients complete Part A and additional sites come online. He notes that this outcome compares favorably with a competing program from Sanofi and may reflect claseprubart’s superior complement-inhibition potency, while new assets DNTH-212 and DNTH-312 add attractive optionality through upcoming external clinical readouts. According to TipRanks, Minter is a 5-star analyst with an average return of 32.2% and a 57.24% success rate. Minter covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Moderna, and Vertex Pharmaceuticals. In another report released on September 11, J.P. Morgan also initiated coverage with a Buy rating on the stock with a $135.00 price target. ### Related Stocks - [DNTH.US](https://longbridge.com/en/quote/DNTH.US.md) - [SNY.US](https://longbridge.com/en/quote/SNY.US.md) - [IONS.US](https://longbridge.com/en/quote/IONS.US.md) - [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md) - [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md) - [JPM.US](https://longbridge.com/en/quote/JPM.US.md) - [SNYNF.US](https://longbridge.com/en/quote/SNYNF.US.md) - [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md) - [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md) - [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md) - [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md) - [8634.JP](https://longbridge.com/en/quote/8634.JP.md) - [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md) - [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md) ## Related News & Research - [Dianthus Therapeutics to present Phase 3 CAPTIVATE interim analysis of claseprubart in CIDP at 2026 AANEM meeting](https://longbridge.com/en/news/300432141.md) - [Dianthus Therapeutics (NASDAQ:DNTH) Coverage Initiated at JPMorgan Chase & Co.](https://longbridge.com/en/news/298733559.md) - [Micron Stock Forecast: 25 Analysts Say Buy, but Goldman Sachs Remains the Lone Hold After Q4 Earnings. Here's Why.](https://longbridge.com/en/news/300934859.md) - [Tesla's Q3 Beat Wins Praise From HSBC but Analyst Still Says 'Sell' on TSLA Stock](https://longbridge.com/en/news/300921335.md) - [Microsoft's blazing stock comeback isn't even close to being over, analyst says](https://longbridge.com/en/news/300955443.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**